Angiomammography and Neoadjuvant Chemotherapy

NCT05402930 | Completed

• 1 other identifier: 2019-4433
• Study Type: interventional
• Target: 67
• Locations: 1 country
• Sites: 1

Brief Summary

The best prognostic factor following neoadjuvant chemotherapy is the pathological complete response (pCR). pCR is defined as the absence of invading cells in the breast and lymph nodes following neoadjuvant chemotherapy treatment. Since patients with pCR have a better prognosis than those without pCR, some studies have evaluated different methods to predict pCR early in treatment. Thus, patients who do not respond optimally to treatment could be identified early and changed treatment in order to maximize the chances of pCR and avoid the morbidity of poorly effective treatments. To do this, several modalities have been proposed, including MRI, mammography, ultrasound, positron emission tomography, elastography, and serial biopsies, but these techniques have shown predictive and sometimes expensive. Nevertheless, assessment of tumor response after cycle 2 has been suggested to be appropriate for the prediction of pCR. The main objective of this study is to compare the performance of two diagnostic modalities, namely CESM and MRI, in the evaluation of the response of a malignant breast tumor to neoadjuvant chemotherapy and the prediction of pCR. The radiological response will also be compared to the clinical response.

Conditions

Breast Neoplasms

Outcome Measures

Primary Outcomes (1)

• Number of patients with a pCR accoreding to angiomammography, based on a 50% reduction in lesion size at angiomammography

  Prediction of pCR using angiomammography after cycle 2 of neoadjuvant chemotherapy, based on a 50% reduction in lesion size at angiomammography

  Cycle 2 (each cycle being 21 days), i.e., after the chemotherapy on day 1 of cycle 2 and before cycle 3.

Study Arms (1)

Neoadjuvant chemotherapy

EXPERIMENTAL

Diagnostic Test: Angiomammography

Interventions

Angiomammography DIAGNOSTIC_TEST

Patients will receive their care in a standard manner. Breast MRI is one modality used by physicians to monitor response to neoadjuvant chemotherapy and will therefore be used as standard. A CESM exam will be added at the same time as the MRI. Patients will have a physical exam, breast MRI and CESM before the start of chemotherapy (less than 2 weeks). These examinations will be repeated after cycle 2 (±1 week) and at the end of chemotherapy. After each cycle of chemotherapy, the tumor will be measured in two axes by the attending physician. Histological examination of the surgical specimen will be used to determine the pCR. Responses observed on MRI and CESM will be compared to pCR.

Neoadjuvant chemotherapy

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Female aged 18 and over
• Histologically proven breast cancer by large gauge needle
• No evidence of distant metastasis
• Neoadjuvant chemotherapy with or without concomitant targeted therapy
• Breast tumor initially measurable by clinical examination

You may not qualify if:

• Refusal to perform the biopsy or surgery
• Pregnant or possibly pregnant woman
• Usual contraindication to contrast product
• Significant kidney failure
• Allergy to contrast medium
• frank hyperthyroidism
• Usual contraindications to MRI

Sponsors & Collaborators

• CHU de Quebec-Universite Laval: lead

Study Sites (1)

St-Sacrement Hospital

Québec, Quebec, G1S4L8, Canada

Location

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 20, 2022
• First Posted: June 2, 2022
• Study Start: January 3, 2018
• Primary Completion: December 31, 2025
• Study Completion: December 31, 2025
• Last Updated: March 19, 2026

Record last verified: 2026-03

Locations

CA (1)